Journal article
The Canadian Experience with Intensive Fluorouracil, Epirubicin and Cyclophosphamide in Patients with Early Stage Breast Cancer
Abstract
A multicentre dose-finding pilot study was conducted to determine an intensive regimen of fluorouracil (F), epirubicin (E) plus cyclophosphamide (C) [FEC] that was tolerable and acceptable to patients with node-positive operable (n = 266) or locally advanced (n = 22) breast cancer. Consecutive patients were treated with fluorouracil and epirubicin administered intravenously on days 1 and 8, in addition to cyclophosphamide orally for 14 days. …
Authors
Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Shillings J
Journal
Drugs, Vol. 45, No. Suppl 2, pp. 51–59
Publisher
Springer Nature
Publication Date
May 1993
DOI
10.2165/00003495-199300452-00009
ISSN
0012-6667